Dupixent's Sales Growth from 2019 to 2020
Dupixent (dupilumab), developed by Sanofi and Regeneron, saw rapid sales increases in its early commercial years, driven by expanding approvals for atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Global net product sales jumped from $2.59 billion in 2019 to $4.56 billion in 2020, nearly doubling year-over-year.[1][2]
Quarterly Breakdown for 2019
Sales built steadily through the year:
- Q1: $523 million
- Q2: $623 million
- Q3: $713 million
- Q4: $729 million
This quarter-on-quarter growth reflected growing physician adoption and label expansions.[1]
Quarterly Breakdown for 2020
Momentum accelerated despite pandemic disruptions, with consistent gains:
- Q1: $967 million
- Q2: $1.14 billion
- Q3: $1.20 billion
- Q4: $1.26 billion
U.S. sales dominated at about 80% of total, while ex-U.S. markets like Europe contributed the rest.[2]
Year-Over-Year Comparison
| Period | 2019 Sales | 2020 Sales | Growth |
|--------|------------|------------|--------|
| Annual | $2.59B | $4.56B | +76% |
| Q1 | $523M | $967M | +85% |
| Q2 | $623M | $1.14B | +83% |
| Q3 | $713M | $1.20B | +68% |
| Q4 | $729M | $1.26B | +73% |[1][2]
What Drove the Surge?
Broader indications boosted prescriptions: asthma approval in late 2018 and nasal polyps in 2019 doubled eligible patients. Pricing held steady around $3,500-$4,000 per dose in the U.S., with volume up 80%.[2][3] COVID-19 slowed some in-person visits but did not derail growth.
How Did This Compare to Competitors?
Dupixent outpaced rivals like Novartis's Cosentyx ($2.8B in 2020) and Eli Lilly's Taltz ($1.9B), capturing over 30% of the biologics market for moderate-to-severe atopic dermatitis.[3]
[1]: Sanofi 2019 Annual Report
[2]: Sanofi 2020 Annual Report
[3]: Regeneron 2020 10-K Filing